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Abstract
Schwannomas are common, highlymorbid andmedically untreatable tumors that can arise in patients with germ line as well
as somatic mutations in neurofibromatosis type 2 (NF2). These mutations most commonly result in the loss of function of the
NF2-encoded protein, Merlin. Little is known about how Merlin functions endogenously as a tumor suppressor and how its
loss leads to oncogenic transformation in Schwann cells (SCs). Here, we identify nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB)-inducing kinase (NIK) as a potential drug target driving NF-κB signaling and Merlin-deficient
schwannoma genesis. Using a genomic approach to profile aberrant tumor signaling pathways, we describe multiple
upregulated NF-κB signaling elements in human and murine schwannomas, leading us to identify a caspase-cleaved,
proteasome-resistant NIK kinase domain fragment that amplifies pathogenic NF-κB signaling. Lentiviral-mediated
transduction of this NIK fragment into normal SCs promotes proliferation, survival, and adhesion while inducing
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schwannoma formation in a novel in vivo orthotopic transplant model. Furthermore, we describe an NF-κB-potentiated
hepatocyte growth factor (HGF) to MET proto-oncogene receptor tyrosine kinase (c-Met) autocrine feed-forward
loop promoting SC proliferation. These innovative studies identify a novel signaling axis underlying schwannoma
formation, revealing new and potentially druggable schwannoma vulnerabilities with future therapeutic potential.
Significance Statement
We report the discovery of a novel, proteasome-resistant frag-
ment of NIK that drives schwannoma formation. This NIK/NF-κB
signaling axis directs an autocrineHGF–c-Met signaling loop that
sustains schwannoma proliferation, identifying vulnerabilities
with future therapeutic potential.
Introduction
Neurofibromatosis type 2 (NF2) is an autosomal dominant neu-
rocutaneous syndrome caused by mutations of the NF2 tumor
suppressor gene that encodes the protein Merlin. NF2 patients
typically present in young adulthood or, less commonly, in
childhood, with multiple intracranial and spinal schwannomas,
meningiomas and ependymomas, resulting in neurologic dis-
ability and earlymortality.Tumor-relatedmorbidities range from
multiple cranial neuropathies to myelopathy and peripheral
neuropathy. Although NF2 is relatively rare (1 in 25 000–33 000
live births), its hallmark tumors [vestibular schwannomas (VSs)
and meningiomas] are the world’s most common adult neural
tumors (1,2). Similar toNF2 patients, these spontaneously arising
tumors demonstrate NF2 mutations. Unfortunately, no medical
alternatives to surgery exist for NF2-associated or spontaneously
arising NF2-mutated tumors, and surgically related morbidities
like permanent loss of nerve function for VS patients are not
uncommon.
Despite the NF2 gene’s identification dating back to 1993
(3), an understanding of the gene product’s (Merlin) tumor
suppressor function remains incomplete. Merlin-deficient
schwannomas have been shown to have hyperactivation of
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) signaling (4,5), but the precise mechanisms by which
Merlin influences NF-κB signaling remain elusive. The NF-κB
signaling pathway and its transcription factors (NF-κB1/p105,
NF-κB2/p100, RELA, RELB and c-REL) mediate organogenesis, cell
proliferation, cell survival, inflammation, and oncogenesis in
many cancers, potentially including human nerve sheath and
glial tumors (6,7).
To interrogate the signaling pathways critical to schwan-
noma pathogenesis, we employed transcriptomic profiling of
primary human schwannomas. Similar approaches utilizing
transcriptomics have yielded unique insights into a related
neurocutaneous syndrome, neurofibromatosis type 1 (8,9).
Consistent with prior findings, human schwannomas displayed
activation of multiple NF-κB-related kinases and increased
expression of NF-κB-related genes. Through the use of our
recently published NF2 mouse model (10), we confirmed
that chronic NF-κB activation was also present in murine
Merlin-deficient schwannomas. Biochemical analyses revealed
that this activated NF-κB signaling depended on ∼55 kDa
NF-κB-inducing kinase (NIK) kinase domain fragment produced
by caspase-8-mediated cleavage. Intriguingly, this fragment
Figure 1. NF-κB pathway activation in schwannomas. (A) IPA of human schwannoma microarray data identifies 2766 differentially regulated genes in the tumor
tissue, 93 of which are NF-κB signaling elements and target genes. (B) Validation of deregulated NF-κB genes by qRT-PCR in primary nerve tissues (WT n = 3; NF2-KO
n = 3). ns = not significant, ∗p < 0.05. Unpaired Student’s t-test with Holm–Sidak correction for multiple comparisons, α = 0.05. Error bars represent standard error of
the mean (SEM). (C) IB demonstrating increased NF-κB transcription factors and signaling elements in NF2-KO nerve tissues. (D) IHC of RELA in murine (upper) and
human (lower) tissues. Scale bar = 20 μm. Original magnification ×400. Arrowheads point to representative nuclei with positive staining for RELA. 1000× insets are
examples of positive nuclear staining. (E) IB of fractionated primary nerve tissue from WT and NF2-KO mice demonstrating increased cytoplasmic and nuclear levels
of RELA and RELB proteins. Vertical bar indicates different exposures. NF2 = NF2-KO, cyto = cytoplasmic fraction, nuc = nuclear fraction. (F) IHC of NIK in murine
(upper) and human (lower) tissues. Scale bar = 20 μm. Original magnification ×400. (G) IB demonstrating the accumulation of fragments of the kinase domain of NIK
including a 55 kDa fragment (red arrowhead). Full-length NIK can be identified by the red asterisk at ∼120 kDa. HVS = spontaneous human vestibular schwannoma.
(H) IB of primary HVS with matching control CN VIII tissues from the surrounding nerve in the same patient.
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demonstrated resistance to the proteasome-mediated degrada-
tion that normally regulates full-length NIK signaling. Schwann
cells (SCs) transduced with this NIK fragment demonstrated
increased proliferation, survival and adhesion and formed
tumors when transplanted into the sciatic nerve of nude
mice. We also describe an NF-κB-driven hepatocyte growth
factor (HGF) to c-Met autocrine feed-forward signaling loop
that sustains schwannoma cell proliferation. In all, this study
reveals that a proteasome-resistant NIK fragment drives
oncogenic NF-κB signaling in Merlin-deficient SCs. With
multiple NIK small molecules currently in preclinical develop-
ment (11,12), these studies provide a novel molecular insight
into schwannoma genesis with highly relevant therapeutic
implications.
Results
The NF-κB pathway is activated in schwannomas
Using microarray data from 31 human VSs in the Gene
Expression Omnibus (GEO) (13,14), we identified differentially
expressed genes (DEGs) which, when input into Ingenuity
Pathway Analysis (IPA; Qiagen, Redwood City, CA, USA) (15),
revealed 93 deregulated NF-κB pathway elements as compared
to normal nerve samples (Fig. 1A, Supplementary Files 1
and 2), including genes identified as either NF2-regulated
or overexpressed in schwannomas (e.g. CCND1 and ERBB2)
(16,17). In corroboration, quantitative real time polymerase
chain reaction (RT-PCR) of schwannomas from our recently
characterizedNF2 tumormodel (Postn-Cre+; Nf2flox/flox;henceforth
NF2-KO) and wild-type (WT) (Postn-Cre−; Nf2flox/flox) nerve tissue
confirmed NF-κB target gene (Fig. 1B) and transcription factor
(Supplementary Material, Fig. 1A) overexpression. Thus, there
appears to be a shared molecular signature between human
and murine schwannomas (10). Immunoblotting demonstrated
increased levels of p100, RELA, RELB and c-REL, proteins encoded
by Nfkb2, Rela, Relb and Rel genes, respectively, and increased
levels of p52 (Fig. 1C), a marker of non-canonical NF-κB (18). We
also observed an increase in p50 but not the precursor protein
p105 (Supplementary Material, Fig. 1B). Immunohistochemistry
(IHC) and fractionated immunoblotting similarly demonstrated
increased total levels and nuclear translocation of the NF-
κB transcriptional activators, RELA and RELB, in human and
murine schwannomas (Fig. 1D and E, Supplementary Material,
Fig. 1C and D). We examined murine schwannomas in dorsal
root ganglia, cranial nerve V (CNV), cranial nerve VIII (CNVIII),
sciatic nerves and cutaneous tissues and have found NF-κB
activation present in all tumors. In all, these transcriptomic
and biochemical analyses reveal a net increase in canonical
and non-canonical NF-κB signaling in human and murine
schwannomas.
Figure 2. Caspase-8 cleaves NIK, resulting in a 55 kDa fragment of the kinase domain. (A) In silico prediction of human NIK cleavage by caspase-8 using Cascleave
2.0 and SitePrediction software programs. (B) IB of 293 T cells transfection experiment demonstrating that caspase-8 activity is sufficient for the cleavage of NIK to
p55 NIK. (C) In vitro cleavage assay with purified NIK and recombinant caspase-8. (D) Co-immunoprecipitation experiment in 293 T cells with IP of FLAG-tagged NIK.
(E) Structure of human NIK. TRAF3-B = TRAF3 binding domain, NRD = Negative Regulatory domain, Kinase= Kinase domain and CTD = C-terminal domain. (F) IB of 293
T cells transfected with the indicated plasmids. Cells were pulsed with proteasome inhibitor MG132, washed and incubated with the protein translation inhibitor CHX.
Number labels indicate hour time course. (G) IB of 293 T cells transfected with the indicated plasmids. (H) Transfection experiment with Cignal-293 T cells in triplicate
possessing an NF-κB responsive promoter upstream of a GFP reporter. ANOVA with Dunnett’s test for post hoc comparisons. ns = not significant, ∗∗∗∗p < 0.0001;
Error bars represent SEM. (I) Repeat of IB in (G) in triplicate showing increased processing of p100 to p52 in 309-801 NIK-transfected cells. (J) Co-immunoprecipitation
experiment in 293 T cells with IP of FLAG-tagged IKKα. The red asterisk in (B) and (C) indicates full-length NIK, while the red arrowhead points to the 55 kDa fragment
of the kinase domain. IB = Immunoblot, IP = Immunoprecipitation, WCL = whole cell lysate.
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We next examined upstream NF-κB regulatory elements in
human and murine schwannomas, finding overexpression of
NIK (Fig. 1F–H, Supplementary Material, Fig. 2A–C). Intriguingly,
immunoblotting of human and murine schwannomas with
a kinase domain-specific peptide antibody revealed not only
increased total NIK but also accumulation of ∼55 kDa NIK
fragment, as compared to non-affected nerve tissue from the
same mouse or patient (Fig. 1G and H, Supplementary Material,
Fig. 2B and C). The NIK kinase domain is constitutively active
(19) and in an in vitro NIK kinase assay using recombinant
IKKα as substrate, we observed over a 50% increase in NIK
kinase activity in murine schwannomas as compared to normal
nerve tissue (Supplementary Material, Fig. 2D). This supports
our hypothesis that the increased endogenous levels of NIK
in the tumor tissues are sufficient to trigger an increase in
substrate phosphorylation and downstream activation NF-κB
transcription factors.
p55 NIK is a proteasome-resistant fragment of NIK
that drives oncogenic signaling in SCs
Given our findings combined with previous observations
that pathologic NIK cleavage drives mucosal associated lym-
phoid tissue (MALT) lymphoma formation (20) and limited
in vitro data showing that caspase-8 can cleave NIK (21),
we hypothesized that caspase-8 may produce a kinase-
active NIK fragment that underlies schwannoma genesis.
An unbiased analysis with Cascleave 2.0 (22) and SitePre-
diction (23) software predicted species-conserved caspase-
8 cleavage clusters in N-terminus sites D291 and D308 and
C-terminus sites D801, D807, D808 and D822 capable of pro-
ducing ∼55 kDa NIK fragments containing the entire kinase
domain (Fig. 2A, Supplementary Material, Fig. 3A and B,
Supplementary Files 3 and 4). Co-transfection of NIK and
caspase-8 into 293 T cells produced a 55 kDa NIK fragment,
Figure 3. NIK critically regulates SC function. (A) 72 h proliferation study inHEI-193 human schwannoma cell line comparing control and three independent NIK shRNAs.
(B) 72 h proliferation study with primary murine schwannoma cells comparing control and four independent NIK shRNAs. In (C)–( J) primary passages 1 and 2 SCs were
stably transduced with an IRES-EGFP control or 309-801 NIK IRES-EGFP expressing lentivirus. (C) Representative images of EdU immunofluorescence experiment. Scale
bar = 20 μm. Original magnification ×200. (D) Quantitation of (C). Over 400 cells were counted of each genotype in total (n = 3 of each). (E) 48 h serum and growth factor
starvation survival assay. (F) iCelligence cell adhesion assay. Adhesion is measured by changes in impedance caused by cells falling out of suspension and depositing
onto electrodes, forming focal adhesion complexes. (G) qRT-PCR in transduced primary SCs. (H) Transplant schema of transduced primary SCs into Foxn1nu nude mice.
(I, upper) Gross images of dissected sciatic nerves from IRES- and NIK-transduced SC transplants. Scale bar = 500 μm. (I, lower) Tabular results from transplant studies
outlined in (H). (J) Serial sections of IRES- and NIK-injected nerves stained with H&E, GFP, RELA and RELB. Original magnification ×100, magnified inset 400×. Scale
bar = 100 μm. [ANOVA with Dunnett’s test (α = 0.05) for post hoc comparisons (A) and (B); Fisher’s exact test (D); unpaired Student’s t-test with Holm–Sidak correction
for multiple comparisons (α = 0.05, E, F, G, and I). ns = not significant, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗∗P < 0.0001. Error bars represent SEM. All experiments with statistical
testing were performed in triplicate.]
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which was diminished by CrmA, a high-affinity caspase-1 and
caspase-8 inhibitor (Fig. 2B). Likewise, incubating purified NIK
with caspase-8 in vitro generated a 55 kDa fragment, which
could be abrogated by the potent caspase inhibitor Q-VD-
Oph (Fig. 2C). Co-immunoprecipitation demonstrated a physical
interaction between NIK and caspase-8 (Fig. 2D). Furthermore,
peptide-based antibodies specifically targeting murine amino
acids 311–328 and a peptide surrounding human residue 659
confirmed that the 55 kDa fragment observed in primary tumor
tissues includes the entire kinase domain of NIK (∼390 to 660
amino acids; Supplementary Material, Fig. 4A and B). Finally,
mass spectroscopy of the purified 55 kDa fragment indepen-
dently revealed 12 unique NIK peptides with near exclusive
coverage of the NIK kinase domain (Supplementary Material,
Fig. 5A–C).
Importantly, this ∼55 kDa NIK fragment (p55 NIK) contains
the functional NIK kinase domain but lacks critical NIK
negative regulatory elements including the TRAF3 binding
domain (TRAF3-B; residues 30–120), the majority of the negative
regulatory domain (NRD; 121–317), the inhibitor of apoptosis
(N-terminus) binding motif, and the destabilizing IKKα phos-
phorylation sites at 809, 812, and 815 (19,24–26) (Fig. 2E). We first
confirmed that p55 NIK migrated similarly to a cDNA construct
encoding NIK residues 309-801, the fragment generated by the
innermost N- and C-termini cleavage sites (Supplementary
Material, Fig. 5D). Hypothesizing that p55 NIK would demon-
strate increased stability,we transfected plasmids encoding full-
length NIK or NIK residues 309-801 into 293 T cells, pulsed with
the proteasome inhibitor MG132, washed and then incubated
for up to 24 h with the translation inhibitor cycloheximide
(CHX). While we could not detect full-length NIK protein in the
absence of proteasome inhibition or after 16 h CHX treatment,
we detected 309-801 NIK at 55 kDa in the same conditions
throughout 24 h CHX (Fig. 2F). Both full-length NIK and p55
NIK induced canonical and non-canonical NF-κB signaling, as
evidenced by increased RELB levels and proteolytic processing
of p100 to p52, respectively (Fig. 2G). Moreover, Cignal-293 T
cells possessing an NF-κB responsive element upstream of GFP
confirmed the 309-801 NIK fragment induces NF-κB activation
(Fig. 2H). Of note, repeated experiments demonstrated that
309-801 NIK more robustly induces p100 processing to p52 as
compared to full-length NIK, suggesting p55 NIK preferentially
enhances non-canonical NF-kB signaling (Fig. 2G and 2I).
Finally, co-immunoprecipitation of p55 NIK with IKKα verified
p55 NIK’s ability to both interact with and phosphorylate its
putative downstream target (Fig. 2J). Thus, p55 NIK resists
proteasome-mediated degradation, retains functional kinase
activity, and may preferentially induce non-canonical NF-kB
signaling.
We next evaluated the functional effects of NIK signaling on
SCs. small hairpin RNA (shRNA)-mediated knockdown of NIK
reduced proliferation in an immortalized human schwannoma
line and primary murine schwannoma cells by roughly
2-fold with multiple independent shRNAs (Fig. 3A and B,
Supplementary Material, Fig. 6A). To examine p55 NIK’s bio-
logical impact on non-transformed primary SCs, we used
lentiviral-mediated transduction to introduce either internal
ribosomal entry site (IRES)-EGFP or 309-801 NIK IRES-EGFP
into passage 1 or 2 (P1-P2) murine SCs, which maintained
S100-positivity during culture (Supplementary Material, Fig. 6B).
309-801 NIK-transduced SCs demonstrated increased S-phase
activity, proliferation, survival and adhesion to poly-D-lysine
(PDL)/laminin-coated plates as measured by iCelligence real-
time monitoring (Fig. 3C–F, Supplementary Material, Fig. 6C).
309-801 NIK fragment expression also increased Ccnd2, Erbb2
and Met messenger RNA and protein (Fig. 3G, Supplementary
Material, Fig. 6D) as well as increased expression of three of
five Rel family transcription factors by RT-PCR and immunoblot
(IB) (Supplementary Material, Fig. 6E–G). Of note, our in silico
analysis and confirmatory studies (Fig. 1) revealed overexpres-
sion of many of the same genes in human VS and murine
schwannomas.
To test the significance of these findings in vivo, we
transduced primary murine SCs with 309-801 NIK IRES-EGFP or
IRES-EGFP and injected 1∗106 cells with basement membrane
matrix into the sciatic nerves of Foxn1-deficient nude mice
(Fig. 3H). Five months later, 309-801 NIK-injected nerves showed
fusiform tumor nodules (Fig. 3I). Of note, two independent
experiments yielded similar results (Fig. 3I, Supplementary
Material, Table 1). Haemotoxylin and eosin (H&E) revealed
focal SCs dysplasia consistent with schwannoma formation,
and IHC demonstrated increased expression of GFP, RELA and
RELB (Fig. 3J). Importantly, the SC nucleocentric RELA and RELB
staining patterns mimicked those seen in murine model and
primary human schwannomas (Fig. 1F, Supplementary Material,
Fig. 1C andD).These studies roundly demonstrate that p55NIK is
sufficient to upregulate NF-κB signaling and transform primary
SCs in vivo.
NF-κB potentiates an HGF–c-MET activation loop
that sustains schwannoma proliferation
c-MET, the receptor for HGF and a known glial cell growth factor,
has previously been implicated in the pathogenesis of schwan-
nomas, though the mechanism of how this occurs remains to
be identified (27–28). IHC of human vestibular schwannoma
revealed marked elevations of c-MET and Phospho-c-MET
(Tyr 1234/1235), a marker of c-MET activation (Fig. 4A). Fur-
thermore, kinome profiling (29), a recently developed mass
spectrometry (MS)-based assay which utilizes kinase-specific
inhibitor beads to measure the activity of up to 275 kinases in a
single tissue lysate sample, revealed a nearly 4-fold increase in c-
MET receptor activation in schwannoma-bearing murine nerve
tissue as compared to control nerve tissues (Fig. 4B). In Figure 3G
and SupplementaryMaterial, Figure 6D,we demonstrate 309-801
NIK upregulates c-MET expression in primary SCs. Conditioned
media from 309-801 NIK-transduced SCs had increased levels of
secreted HGF with no change in neuregulin 1 (NRG1), indicating
that NF-kB activation in tumorigenic SCs may also be capable
of promoting HGF secretion (Fig. 4C). AliBaba 2.1 software
predicted NF-κB binding motifs at −67 (ATTTCCCTCT), −350
(CTTCCCGGGG), −566 (AAACTCCTCT) and −584 (GGAAGTCTCC)
and chromatin immunoprecipitation-quantitative polymerase
chain reaction (ChIP-qPCR) of the MET promoter using anti-
RELA antibody in three patient-derived VS amplified a region at
−199, corresponding to strong RELA binding at theMET promoter
(Fig. 4D), further supporting the notion that NF-kB activation is
responsible for the increased expression of c-MET we observe in
schwannomas.
Examination of 309-801 NIK transplanted schwannoma
tumors revealed elevations of c-MET and Phospho-c-MET in the
murine tumor-bearing tissues, consistent with the hypothesis
outlined in the above paragraph (Fig. 4E). Finally, in vitro
proliferation studies demonstrated primary NF2-KO SCs were
over twice as sensitive to HGF stimulation as WT SCs, indicating
that c-Met activation can be strongly mitogenic in tumorigenic
SCs (Fig. 4F). These data support c-Met playing a central role
in schwannoma development, with NF-κB critically regulating
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Figure 4. NIK and NF-κB regulate pathologic activation of MET signaling in schwannomas. (A) IHC of MET and Phospho-MET in human nerve tissue and three distinct
HVS. Scale bar = 20 μm. Original magnification ×400. Arrowheads point to representative cells with positive staining for Phospho-MET. (B) Kinome analysis in primary
murine tissues demonstrating a nearly 4-fold statistically significant increase in MET activation in schwannomas. The dotted line indicates a false discovery rate of
5% (Benjamini–Hochberg correction). (C) ELISA of SC-conditioned medium collected after 96 h of incubation. (D) ChIP-qPCR of human MET promoter region with an
antibody targeting RELA. The graph displays the MET promoter region and PCR primers flanking locations at −199 and −793. Untr12 primers serve as a negative control
and BIRC3 as a positive control. TSS = transcriptional start site. (E) Serial sections of IRES- and NIK-injected nerves stained with H&E, MET and Phospho-MET from the
experiment outlined in Figure 3H. Original magnification ×100, magnified inset 400×. Scale bar = 100 μm. (F) In vitro cell counting assay with primary NF2-KO and WT
murine schwannoma/SCs over 10 days. [Unpaired Student’s t-test with Holm–Sidak correction for multiple comparisons (α = 0.05; C). Two-way ANOVA with Dunnett’s
test for post hoc comparisons (α = 0.05, D and F). ns = not significant, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. Error bars represent SEM. All experiments with
statistical testing were performed in triplicate.]
a feed-forward HGF/MET signaling loop that may initiate and
sustain NF2-deficient SC tumor formation (30–31).
Discussion
Our data directly implicate NIK/NF-κB as the putative driver of
schwannoma genesis, of which there are a number of preclinical
drugs in the early stages of development (32). Currently, our
understanding of how the loss of NF2 leads to NF-κB is lim-
ited. Previously, Merlin has been shown to bind to large tumor
suppressor kinase 1/2 (LATS1/2), leading to phosphorylation of
LATS1/2 and suppression of the Hippo signaling transcription
factors YAP and TAZ, suggesting a critical role for NF2 and the
Hippo pathway in branching morphogenesis (33). Prior studies
have linked activation of the Hippo pathway to activation of NF-
κB (34). Thus, it is possible that Hippo signaling connects loss
of functional Merlin to the activation of NF-κB we observe in
our tumors. We and others are currently exploring the crosstalk
between these pathways in our recently published NF2 mouse
model (17).
We further describe an NF-κB-initiated autocrine HGF/c-MET
signaling loop that selectively promotes the growth of Merlin-
deficient SCs. Activation of c-MET can occur through at least
three mechanisms: in response to its ligand HGF, via integrins
and via dimerization with ErbB family receptors; the latter two
of which are also overexpressed in schwannomas (35–37). Thus,
there are multiple avenues leading to the c-MET activation
observed in schwannomas, suggesting c-MET may be a critical
signaling node in these tumors and, consequently, an excellent
therapeutic target. Future genetic and pharmacologic in vitro and
in vivo studies are warranted to better evaluate c-MET inhibition
as a therapeutic option.
Our studies delineate molecular effectors of schwannoma
genesis while elucidating mechanisms pertinent to broader
investigations of NF-kB signaling in normal and diseased states.
NIK N- and C-termini caspase cleavage sites are conserved
across species, suggesting that these sites critically regulate
NIK biology (Supplementary Material, Fig. 3). We conclude that
the deregulated NIK kinase domain fragment activity explains,
at least in part, the functional relevance of caspase-mediated
NF-κB signaling, an area that deserves much greater attention
(21,38). We additionally provide compelling evidence of a
particular signaling pathway’s influence on schwannoma for-
mation, highlighting a downstream NF-κB-mediated c-MET/HGF
signaling loop with tremendous therapeutic opportunity given
the availability of preclinical and clinically available drugs
targeting both NF-κB signaling and c-MET. Furthermore, our
orthotopic transplant model provides a reproducible tool
for generating schwannomas molecularly and histologically
identical to those observed in humans and mice. Of note,
the studies presented here principally rest upon observations
in primary murine model and human schwannoma tissues,
strongly arguing for the broad relevance of our conclusions to
NF2, SC and NF-κB biology writ large.
Materials and Methods
Animal and human study approval
Animal studieswere conducted in accordancewith and approval
of Institutional Animal Care and Use Committee of Indiana
University Medical School, the US Department of Agriculture’s
Animal Welfare Act and the Guide for the Care and Use of
Laboratory Animals. Human studies were conducted under IRB
approval (IRB# 1107006213, ‘Genotype, Phenotype, and Treat-
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ment of Human Vestibular Schwannomas’). Details of our NF2
model can be found in the initial publication (10).
Statistical methods
Statistical analyses were performed with GraphPad Prism 6.0.
and 7.0. As noted in the text, analysis of variance (ANOVA)
or Student’s t-test was used to test for differences between
samples. When applicable, corrections were made for multiple
testing. Specific tests and significance levels can be found in the
figures and figure legends.
Microarray and IPA
Previously published schwannomamicroarray data (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE39645, Torres-Martin
et al., Int. J. Oncol., 2013) were downloaded from the GEO and
loaded into Partek Genomics Suite (Partek Inc., St. Louis, MO,
USA). In our analysis, we included 31 schwannoma samples
and 8 control samples (the human SC line group was excluded
from the controls). The data were then quantile normalized
and DEGs were identified by ANOVA as those having P-values
<0.05. The Benjamini and Hochberg method was used to correct
for multiple testing. Further, filtering of DEGs was completed
to remove genes with fold changes between −2 and 2. Net-
work analysis was then completed with this DEG set with IPA
(www.qiagen.com/ingenuity). Microarray analysis and IPA were
completed by the Indiana University School of Medicine Center
for Computational Biology and Bioinformatics.
Preparation of mouse trigeminal nerves for RNA
and protein studies
Mice were sacrificed and trigeminal nerve tissue was freshly
dissected, minced with a scalpel and washed 3× with cold
phosphate-buffered saline (PBS), pelleting the tissue in between
washes using a tabletop centrifuge (Eppendorf, Enfield, CT, USA)
at 4◦C. Tissue was then prepared for protein or RNA studies. For
whole lysate protein studies, xTractor Lysis buffer (Takara Bio,
Mountain View,CA,USA)with cOmplete Protease Inhibitor Cock-
tail (Roche, Indianapolis, IN, USA) and PhosSTOP Phosphatase
Inhibitor Cocktail (Roche, Indianapolis, IN, USA) was incubated
with the tissues. This mixture was then sonicated on ice, spun
down at max speed on a tabletop centrifuge for 10 min at
4◦C and the supernatant was collected and stored at −80◦C
for future use. Trigeminal nerve tissue was fractionated into
cytoplasmic and nuclear protein fractions using the NE-PER
subcellular fractionation kit (Thermo Fisher Scientific, Federal
Way, WA, USA). Proteins were standardized by bicinchoninic
acid assay (BCA) in all immunoblotting studies. For RNA extrac-
tion, tissues were suspended in RNALater (Thermo Fisher Sci-
entific, Federal Way, WA, USA) and stored at −20◦C and later
harvestedwith Trizol (Thermo Fisher Scientific, FederalWay,WA,
USA).
Histology and IHC
Tissues were excised from recently sacrificed animals, fixed
with 10% formalin, embedded in paraffin and sectioned. IHC on
formalin-fixed, paraffin-embedded mouse and human samples
was completed by the Indiana University School of Medicine
Immunohistochemistry Core. Schwannoma tissue microarrays
(US Biomax, Rockville, MD, USA) were also completed by the
Indiana University School of Medicine Immunohistochemistry
Core.
Cell culture and transfection
HEK-293 T and HEI-193 cells (American Type Culture Collection,
Manassas,VA,USA) were used for transfection experimentswith
polyethyleneimine (PEI; Millipore-Sigma, St. Louis, MO, USA).
Unless otherwise noted, Dulbecco’s Modified Eagle Medium
(DMEM; Thermo Fisher Scientific, Federal Way, WA, USA)
containing 10% fetal bovine serum (FBS; Millipore-Sigma, St.
Louis, MO, USA), 50 U/ml penicillin, 50 μg/ml streptomycin
and 2 mm L-glutamine (Lonza, Allendale, NJ, USA) was used
for cell culture. For creation of a stable NF-κB reporter cell
line, 293 T cells were transduced with Cignal NF-κB GFP
Reporter Lentivirus (Qiagen) and selected with puromycin
(Millipore-Sigma, St. Louis, MO, USA). The Cignal NF-κB GFP
Reporter Lentivirus stably inserts a modified form of the GFP
gene under the control of a minimal CMV promoter with
tandem repeats of the canonical NF-κB transcriptional response
element. Both 293 T and HEI-193 cell lines were tested for
mycoplasma using a PCR kit from Lonza (MycoAlert). Cell
lines were used in experimentation prior to 30 passages after
thawing.
Primary SC procurement and culture
WT embryonic day 13.5 embryos were harvested from pregnant
dams after sacrifice. Embryos were placed in cold PBS + 1%
Pen/Strep (Lonza, Allendale, NJ, USA, 10K/10K) and the dorsal
root ganglion (DRG) were dissected from each embryo with
the aid of a dissecting microscope. All DRGs isolated from
an individual were pooled and placed into a tube containing
500 μl of DMEM + 10% FBS and placed on ice. The DRGs
were then digested in 0.05% trypsin-EDTA (Thermo Fisher
Scientific, Federal Way, WA, USA) and dissociated with syringes.
DRGs pooled from a single embryo were then plated on PDL
(0.1 mg/ml)/laminin (0.25 mg/ml; Millipore-Sigma, St. Louis, MO,
USA)-coated 12 well plates at one embryo per well in SC Media
I (SCM-I) comprised of DMEM with 50 U/ml penicillin, 50 μg/ml
streptomycin, 2 mm L-glutamine (Lonza, Allendale, NJ, USA),
1X N2 supplement (Thermo Fisher Scientific, Federal Way, WA,
USA) and 250 ng/ml Nerve Growth Factor (NGF, Millipore-Sigma,
St. Louis, MO, USA). The following day, the mediumwas changed
to SC Media II (SCM-II), which was identical to SCM-I except
for the substitution of 2 μm forskolin and 10 ng/ml neuregulin
(Millipore-Sigma, St. Louis, MO, USA) for NGF. Embryonic SCs
were used for all experiments save for those shown in Figure 4F,
where adult primary SCs were used. These were harvested from
the trigeminal nerves of adult mice with a 30 min Collagenase
A (2 mg/ml; Millipore-Sigma, St. Louis, MO, USA) and 20 min
trypsin (0.25%; Thermo Fisher Scientific, Federal Way, WA, USA)
digestion. After 7 days in culture in 10% FBS /DMEM medium on
PDL/laminin-coated plates, cells were expanded and cultured
in 10% FBS/10% human melanocyte growth serum/DMEM
solution (10% media; Thermo Fisher Scientific, Federal Way,
WA, USA).
Orthotopic transplant studies
One million primary SCs (P1-P2) were transduced with IRES-
EGFP or 309-801 NIK lentivirus and transplanted into the sciatic
nerves of female B6.Cg-Foxn1/J (nude) mice purchased from
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Jackson laboratories, Bar Harbor, ME, USA. Mice were roughly
8–12 weeks old at the time of experimentation. Each mouse
was anesthetized with isofluorane and buprenorphine and a
small incision was made using an 11 blade surgical scalpel.
The sciatic nerve was then exposed with blunt dissection
using scissors under a dissecting microscope. A 1:1 admixture
of suspended SC and Culture® basement membrane extract
(Trevigen, Gaithersburg, MD, USA) totaling 20 μl was injected
into the right sciatic nerve of each mouse using a 33 gauge
syringe (Hamilton, Reno, NV, USA). The wound was then closed
with vetbond in experiment #1 and 5-0 prolene suture in
experiment #2.
Kinome studies
Isolation and measurement of the activation of endogenous
protein kinases from SCs were carried out using multiplexed
kinase inhibitor beads and mass spectrometry (MIB/MS). Tis-
sue lysates were sonicated, filtered, pre-cleared with blocked
Sepharose beads and then passed over MIB columns. Pelleted
protein is digestedwith trypsin andpeptides purified onC18 spin
columns. Kinase peptides are labeled with TMT isobaric mass
tags, which provide a quantitative method to determine relative
differences across samples and between treatments. Labeled
kinase peptides are then analyzed using liquid chromatogra-
phy/mass spectroscopy (LC/MS) on a Q-exactive mass spec-
trometer and sequence-identified using Proteome Discoverer 1.3
(Thermo Fisher Scientific, Federal Way,WA, USA) using MASCOT
2.2.4 and SEQUEST databases. Statistically significant kinase
identifications are declared by adjusting for multiple compar-
isons using false discovery rate. In general, we are interested
in kinases that are either upregulated or downregulated by at
least 3-fold in two independent experiments. Examples of such
analyses are shown in a recent publication (29). For the study in
Figure 4, flash frozen tissue (NF2-KO schwannoma DRG or WT
sciatic nerve, n = 3 of each) was processed for MIB/MS analysis.
MIB-binding differences were compared (schwannoma versus
WT) and the log2 difference in binding (schwannoma versus
WT) was plotted versus the –log10 adjusted P-value (Benjamini–
Hochberg correction). The dotted line indicates a false discovery
rate of 5%.
RNA extraction from trigeminal nerves
and primary SCs
RNA extraction, cDNA synthesis, qRT-PCR, data acquisition,
analysis and quality control (QC) of mouse trigeminal nerve
samples were completed by Genome Explorations USA (Mem-
phis, TN). All other RNA work was completed at Indiana
University School of Medicine. RNA was extracted and purified
from primary SCs with Trizol (Thermo Fisher Scientific, Federal
Way, WA, USA) and the PureLink RNA Mini Kit (Thermo
Fisher Scientific, Federal Way, WA, USA). QuantiTect Reverse
Transcription Kit (Qiagen) and Fast SYBR Green Real-Time
PCR Master Mix (Thermo Fisher Scientific, Federal Way, WA,
USA) were then used for two-step qRT-PCR with an ABI
7500 Fast thermal cycler. Expression of GAPDH is used for
normalization.
Primary antibody list
The following antibodies were used for western blotting exper-
iments: RELA (Cell Signaling, Danvers, MA, USA, #8242), RELB
(Cell Signaling #4954), p100/p52 (Cell Signaling, Danvers, MA,
USA, #4882), c-REL (Cell Signaling, Danvers, MA, USA, #12707),
GAPDH (Cell Signaling, Danvers, MA, USA, #5174), NIK (Cell Sig-
naling, Danvers, MA, USA, #4994), IKKα (Cell Signaling, Danvers,
MA, USA, #2682), IκBα (Cell Signaling #4814), Myc (Cell Signal-
ing, Danvers, MA, USA, #2278), HA (Cell Signaling, Danvers, MA,
USA, #3724), FLAG (Cell Signaling, Danvers, MA, USA, #8146),
NF2 (Abcam ab30329), ERBB2 (Pierce, MA5-14057), Phospho-MET
(Millipore-Sigma, St. Louis, MO, USA, SAB4300182), c-MET (Santa
Cruz sc-161), pIKKα (Cell Signaling, Danvers, MA, USA, #2697),
p105/p50 (Cell Signaling,Danvers,MA,USA,#13586) and caspase-
8 (Santa Cruz sc-6136). The custom polyclonal NIK antibody
targetingmurine NIK residues 311:328 was generated by Thermo
Pierce custom antibody services. In all western blots, GAPDH
was used as the loading control. For IHC/immunofluorescence
(IF), the following antibodies were used: RELA (Santa Cruz sc-
109), RELB (Santa Cruz sc-226), NIK (Santa Cruz sc-7211), GFP
(Abcam,Cambridge,MA, USA, ab1218), MET (Santa Cruz sc-8057),
Phospho-MET (Cell Signaling,Danvers,MA,USA, #3077) and S100
(Dako, Carpinteria, CA, USA, IS504).
In vitro kinase assay
Freshly dissected trigeminal nerves from four WT and four
NF2-KO mice were pooled according to genotype and lysed
with immunoprecipitation (IP) lysis buffer (2.5 mm HEPES
pH 7.4, 150 mm NaCL, 1 mm EDTA, 1% Triton X-100, 0.02%
NaN3) and immunoprecipitated with anti-NIK antibody (Cell
Signaling, Danvers, MA, USA, #4994) and agarose-conjugated
protein A/G beads (Santa Cruz sc-2003). Recombinant IKKα
was purchased from Abcam. The in vitro kinase assay was
performed in 30 μl total, comprised of 10× kinase buffer, H20,
P32-ATP, substrate and the IP pellet. The reaction mixture was
incubated for 30 min, separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and developed by
autoradiography.
Western blot densitometry
Western blot filmwas scanned into a digital format and intensity
values were determined using the Image Studio Lite Version 3.1
(LI-COR Biosciences, Lincoln, NE, USA).
Virus generation and titration
The puc2CL6IEGwo lentiviral IRES-EGFP construct was a kind
gift of Helmut Hannenberg at Indiana University School of
Medicine. C-terminus FLAG-tagged NIK was cloned into the
puc2CL6IEGwo construct using the EcoRI and BamHI cloning
sites. The puc2CL6IEGwo construct contains an IRES-EGFP cas-
sette and multiple cloning site downstream of the spleen focus-
forming virus promoter, which robustly drives transcription
in eukaryotic cells. To generate virus, 293 T cells grown to 70%
confluence were transfected with 10 μg each of C-FLAG 309-
801 NIK puc2CL6IEGwo (Lenti 309-801 NIK) or empty vector
puc2CL6IEGwo (Lenti IRES EGFP), 5 μg of gag-pol expressing
plasmid and 1 μg of foamyviral envelope containing plasmid
(PCOPE01) in 6ml of DMEMcontaining 10% FBS and 0.0075mg/ml
PEI (Millipore-Sigma, St. Louis, MO, USA). After roughly 16 h
of transfection at 37◦C, transfection medium was replaced
with 6 ml fresh DMEM containing 10% FBS, 50 U/ml penicillin,
50 μg/ml streptomycin and 2 mm L-glutamine (Millipore-Sigma,
St. Louis, MO, USA). After 24 h, cultures were collected and
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filtered through a 0.22 μm polyethersulfone membrane Stericup
unit (Millipore-Sigma, St. Louis, MO, USA) and centrifuged
at 30 000 × g at 4◦C for 2 h in a polycarbonate Oak Ridge
Centrifuge Tube (Thermo Fisher Scientific, Federal Way, WA,
USA). Supernatant was then decanted, bleached and placed in
biohazard waste. The viral pellet was then resuspended in 1 ml
of DMEMcontaining 10%FBS.Viruswas then stored in aliquots at
−80◦C.Titration of virus to calculate effective infectious particles
per unit volume was determined by percent GFP-positivity (as
measured by flow cytometry) of serially transduced HT1080
cells plated at 100 000 per well on a 6 well plates in 1 ml of
DMEM/10% FBS. Serial dilutions started at 10−3 and ended with
10−8 dilution.
Transduction of primary SCs
Three days after harvesting and platingWTSCs on 12well plates,
cells were then transduced with lentivirus in 1 ml of SCM-II at a
multiplicity of infection (MOI) of 20 (based on an approximate
cell number of 200 000 cells per well). Cells were incubated in
SCM-II (see Primary SC procurement and culture) with virus for
72 h before replating. All experiments utilized P1 SCs.
Fluorescent microscopy
Cells were fixed in 4% paraformaldehyde on coverslips in 12 well
plates (BD Falcon). Following fixation, coverslips were washed
2× in PBS and permeabilized in 0.2% Triton X-100 in PBS and
blocked in 0.2%Triton X-100, 2% BSA in PBS.Coverslipswere then
incubated with primary antibody in 1% BSA in PBS overnight
at 4◦C, washed 3× in PBS and subsequently incubated for 1 h
at room temperature with fluorophore-conjugated anti-mouse
or anti-rabbit antibodies (Thermo Fisher Scientific, Federal Way,
WA, USA). After washing in PBS 3×, they were then incubated in
PBS containingHoechst and to stain the nuclei, respectively.Cov-
erslips were then sealed on microscope slides (Thermo Fisher
Scientific, Federal Way,WA, USA) with lacquer and were allowed
to dry overnight.Datawere acquired on aDeltaVision deconvolu-
tion microscopy system (Thermo Fisher Scientific, Federal Way,
WA, USA).
ChIP-qPCR on primary tumor tissue
Primary patient-derived human vestibular schwannoma sam-
ples were snap frozen and sent to Active Motif (Carlsbad,
CA) for completion of the ChIP-qPCR experiment. After ChIP
was performed, qPCR reactions were set up in triplicate for
each ChIP sample. Each qPCR plate also contained input DNA
and a standard curve for normalization. Normalized data
are expressed as binding events detected per 1000 Cells. The
MET primers used in the experiment are as follows: forward
primer MET-199 = GACTCGGTCCCGCTTATCTC, reverse primer
MET-199 = GCCCACGACAAGGTGAAAC, forward primer MET-
793 = CCTTTGAGTGTTCATTTACTCTTG and reverse primer
MET-793 = TTGTGTTGGGATAACTTTGTATTTC. Specific details
on the data normalization can be found at https://www.
activemotif.com/documents/1837.pdf.
Mass spectroscopy
Excised gel bands were first destained, reduced with 5 mm
Tris(2-carboxyethyl)phosphinehydrochloride and then alkylated
with10 mm chloroacetamide. Alkylated samples were digested
by trypsin (Promega Gold, Sunnyvale, CA, USA) overnight at
37◦C. Digested peptides were extracted from the gel spots with
(1) 50% acetonitrile/49.9%H2O/0.1% trifluoroacetic acid and (2)
99.9% acetonitrile/0.1% trifluoroacetic acid. The instruments
used for analysis were the Thermo Fisher Scientific Orbitrap
Velos Pro and Thermo Dionex UltiMate 3000 RSLC nano system.
Digested peptides were injected onto the C18 column. Peptides
were eluted with a linear gradient from 3 to 40% acetonitrile (in
water with 0.1% trifluoroacetic acid) developed over 70 min at
room temperature at a flow rate of 300 nL/min, and effluent was
electro-sprayed into the mass spectrometer. A blank was run
prior to the sample run to make sure there was no significant
signal from solvents or the column.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) kits for murine
HGF and NRG1 were purchased from R&D Biosystems, Oakville,
ON, Canada and USCN Lifescience Inc., Houston, TX, USA,
respectively. Experimental design details can be found in
Figure 4. Each experiment represents a minimum of three
biological replicates.
Plasmids
C-terminal Myc/FLAG-tagged full-length NIK and Caspase-8
cDNAs in the PCMV6-Entry vector were purchased from Origene.
The Caspase-8 cDNA was then shuttled into the PCMV6-AC-
HA backbone (Origene, Rockville, MD, USA) using the Sgf1
and Mlu1 restriction sites. C-Flag full-length NIK and 309-
801 NIK were PCR-amplified (adding epitope tag sequences
and cloning sites) using Phusion Hi-Fidelity polymerase (New
England Biolabs,Ipswich,MA,USA) from a vector containing full-
length NIK, subcloned into a TOPO-TA cloning vector (Thermo
Fisher Scientific, Federal Way, WA, USA) and then cloned into
the PCMV6-XL5 backbone (Origene, Rockville, MD, USA) using
the EcoRI and SalI cloning sites. The pCR-FLAG-IKKalpha-KM,
pFlag-CrmA and pcDNA-CrmA plasmids were acquired from
Addgene.
SC proliferation assays
Unless otherwise noted, SC-based experiments utilized primary
P1-P2 embryonic SCs.
Hemocytometer-based. 200 000 SCs of each genotype were
seeded in triplicate on a PDL/laminin-coated 12 well plates and
were allowed to adhere overnight. The following morning, the
medium was changed to fresh SCM-II, and 72 h later the cell
number in each well was calculated by trypan blue exclusion
with a hemocytometer.
EdU with fluorescent microscopy. 200 000 SCs of each genotype
were plated on coated coverslips in 12 well plates. The following
morning, the medium was changed to fresh SCM-II with 10 μm
EdU. Cells were pulsed for 8 h and fixed. Life Technologies
Alexa 594 EdU Imaging Kit was used to complete the staining
of the cells. Coverslips were then imaged on the deconvolution
microscope.
SC survival assay
In a PDL/laminin-coated 12 well plates, 200 000 SCs of each
genotype were seeded in triplicate and were allowed to adhere
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overnight. The following day, the medium was removed, cells
were washed 1× with PBS and growth-factor free DMEM with
50 U/ml penicillin, 50 μg/ml streptomycin and 2mm L-glutamine
was added. The number of living cells in each well was counted
48 h later by trypan blue exclusion with a hemocytometer.
SC adhesion assay
For measurement of cell adhesion, the ACEA iCelligence system
was used. The iCelligence system uses an impedance calcu-
lation that allows for real-time monitoring of diverse cellular
processes, including cellular adhesion. Adhesion is measured by
changes in impedance caused by cells falling out of suspension
and depositing onto electrodes, forming focal adhesion com-
plexes. E-plates (ACEA) were coated with PDL/laminin and 250 μl
of SCM-II was added to the plates to take an initial impedance
reading. Next, IRES-EGFP and 309-801 NIK SCs were added to the
wells at 25 000 cells/well with a final volume of 500 μl. Impedance
values were measured every second for the following 3 h.
HGF and SC experiments
In Figure 4F, SCs were plated on PDL/laminin-coated wells in
24 well plates and incubated with the indicated medium over
the course of 10 days. Cell counts were then determined by
hemocytometer counts.
NIK shRNA studies
The HEI-193 human schwannoma cell line was transduced
with lentivirus (Sigma control shRNA SHC004 targeting GFP
and Sigma NIK shRNAs TRCN0000010542, TRCN0000196415,
TRCN0000199183) and selected with puromycin (Millipore-
Sigma, St. Louis, MO, USA). Cells were plated in 12 well
plates at 100 000 cells per well in triplicate. After 3 days in
culture, cells were detached and counted by hemocytome-
ter. Analogous studies were performed in primary NF2-KO
schwannoma cells cultured from the peripheral nerve of a NF2-
KO mouse. For these studies, Sigma control shRNA SHC007
targeting luciferase and Sigma NIK shRNAs TRCN0000012763,
TRCN0000012764, TRCN0000012765 and TRCN0000012767 were
used. The pLKO.1-puro lentiviral backbone was used for all
shRNA studies, which were performed independently a mini-
mum of three times.
CHX NIK protein stability experiment
293 T cells at 70% confluency in 10 cm dishes (BD Falcon) were
transfected with 4 μg/dish of full-length N-Myc NIK or N-Myc
309-801 NIK for 36 h prior to addition of media containing 20 μm
of MG132 (Millipore-Sigma, St. Louis, MO, USA) for 5 h. MG132
was then washed out and medium containing 10 μg/ml of CHX
(Millipore-Sigma, St. Louis,MO,USA) was added to the cells. Cells
were then lysed at the indicated conditions/time points and the
proteins visualized by SDS-PAGE and western blot.
Immunoprecipitation experiments in 293 T cells
Immunoprecipitation experimentswere completed in 293 T cells
transfected with the indicated plasmids/concentrations at 70%
confluency in 10 cm dishes. Two days after transfection, cells
were lysed with radioimmunoprecipitation assay buffer (RIPA)
buffer (50 mm Tris-HCl pH 8.0, 150 mm NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, 0.1% SDS, protease and phosphatase
inhibitors), sonicated and samples were standardized by BCA.
Samples were then incubated overnight with M2 Flag Affinity
Gel (Millipore-Sigma, St. Louis, MO, USA). Immunoprecipitated
proteins were then visualized by SDS-PAGE and western blot.
In vitro caspase-8 cleavage assay
Purification of FLAG-NIK. FLAG-NIKwas transfected at 20 μg/dish
in 70% confluent 15 cm dishes and harvested 48 h later in lysis
buffer (25 mm HEPES pH 7.4, 150 mm NaCl, 1 mm EDTA, 1% Triton
X-100, protease and phosphatase inhibitors) and sonicated.
These samples were then incubated overnight with M2 Flag
Affinity Gel. Flag NIK was then eluted from the resin with 100 μl
of Flag peptide elution solution (200 μg/ml in tris-buffered saline
(TBS); Millipore-Sigma, St. Louis, MO, USA).
In vitro Caspase-8 cleavage of NIK. 200 ng of activated Caspase-
8(BD) was added to 200 ng of purified NIK protein in a 50 μl
volume of reaction buffer (20 mm HEPES pH 7.4, 20 mm NaCl,
1 mm EDTA, 1 mm EGTA, 1.5 mm MgCL2, 10 mm DTT) for 1 h
at 37◦C. Q-VD-Oph, an irreversible pan-caspase inhibitor, was
purchased from ApexBio, Boston, MA, USA.
Prediction of caspase-8 cleavage sites and orthologous
cleavage site analysis
Caspase-8 cleavage sites were predicted for human NIK using
two different applications, Cascleave 2.0 and SitePrediction.
Cascleave 2.0 was set to a medium stringency threshold for
prediction of cleavage sites. The NCBI homologene application
was used to identify orthologous cleavage sites in chimpanzee,
macaque, mouse, rat, dog and cow.
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